EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

The Role of STING-Mediated Activation of Dendritic Cells in Cancer Immunotherapy

Ana R S Ribeiro iD, Theresa Neuper, Jutta Horejs-Hoeck

International Journal of Nanomedicine · 2024

DOI: 10.2147/ijn.s477320 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2024. Verfasst von Ana R S Ribeiro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria. Hauptthemen laut MEDLINE: Dendritic Cells, Neoplasms, Membrane Proteins, Immunotherapy. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The signaling pathway that comprises cyclic guanosine monophosphate-adenosine monophosphate (cGAMP or GMP-AMP) synthase (cGAS) and Stimulator of Interferon Genes (STING) is emerging as a druggable target for immunotherapy, with tumor-resident dendritic cells (DC) playing a critical role in mediating its effects. The STING receptor is part of the DNA-sensing cellular machinery, that can trigger the secretion of pro-inflammatory mediators, priming effector T cells and initiating specific antitumor responses. Yet, recent studies have highlighted the dual role of STING activation in the context of cancer: STING can either promote antitumor responses or enhance tumor progression. This dichotomy often depends on the cell type in which cGAS-STING signaling is induced and the activation mode, namely acute versus chronic. Of note, STING activation at the DC level appears to be particularly important for tumor eradication. This review outlines the contribution of the different conventional and plasmacytoid DC subsets and describes the mechanisms underlying STING-mediated activation of DCs in cancer. We further highlight how the STING pathway plays an intricate role in modulating the function of DCs embedded in tumor tissue. Additionally, we discuss the strategies being employed to harness STING activation for cancer treatment, such as the development of synthetic agonists and nano-based delivery systems, spotlighting the current techniques used to prompt STING engagement specifically in DCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsNeoplasmsMembrane ProteinsImmunotherapySignal TransductionHumansAnimalsNucleotidyltransferasesNucleotides, CyclicSTING Protein

Stichwörter der Autor:innen

cGAS-STING pathwaycancer immunotherapydendritic cellnanoparticle

Substanzen

Membrane ProteinsNucleotidyltransferasesNucleotides, CyclicSTING1 protein, humanSTING Protein

Autor:innen und Institutionen

  • Department of Biosciences and Medical Biology, Paris Lodron University of Salzburg, Salzburg, Austria.
  • Cancer Cluster Salzburg (CCS), Salzburg, 5020, Austria.
  • Center for Tumor biology and Immunology (CTBI), Salzburg, 5020, Austria.

ORCID-Profile: Ana R S Ribeiro

Zitieren

APA

Ribeiro, A. R. S., Neuper, T., & Horejs-Hoeck, J. (2024). The Role of STING-Mediated Activation of Dendritic Cells in Cancer Immunotherapy. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s477320

Vancouver

Ribeiro ARS, Neuper T, Horejs-Hoeck J. The Role of STING-Mediated Activation of Dendritic Cells in Cancer Immunotherapy. International Journal of Nanomedicine. 2024. doi:10.2147/ijn.s477320

BibTeX
@article{Ribeiro2024,
  author = {Ribeiro, Ana R S and Neuper, Theresa and Horejs-Hoeck, Jutta},
  title = {The Role of STING-Mediated Activation of Dendritic Cells in Cancer Immunotherapy},
  journal = {International Journal of Nanomedicine},
  year = {2024},
  doi = {10.2147/ijn.s477320}
}
Kostenlos starten →